Biogen is the big loser in an annual review of biopharma brand values. After a year in which lawmakers accused Biogen of “inappropriately” collaborating with the FDA and setting an ...

Biogen’s new CEO Christopher Viehbacher has wasted no time getting a pipeline re-prioritization underway while signaling that the formerly restrained company is ready to make some deals.

Shares of Biogen Inc. BIIB advanced 2.12% to $133.13 Friday, on what proved to be an all-around positive trading session for ...

The decision was closely watched by patient advocates and scientists alike because Eisai and Biogen's drug, sold under the brand name Leqembi, is the first beta amyloid-targeting medication to ...

The stock's fall snapped a three-day winning streak.

For decades, Biogen has built a legacy in neuroscience ... of employees who are extremely smart,” she said in a STAT Brand Studio multimedia lounge interview at the Summit.

Biogen is a biotech company best known for its ... The drug, which will be sold under the brand name Leqembi, was developed with Japanese pharmaceutical company Eisai. In trials, the drug slowed ...

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

Biogen reported third-quarter revenue of about $2.5 billion ... driven by better-than-expected revenue from some in-line brands. SMA drug Spinraza brought in $431 million during the quarter (versus ...

While Biogen’s financials are in rough shape now, the company’s CEO, Chris Viebacher, sees reason to be optimistic about the future. In fact, with four drug launches rolling and the majority ...

Biosimilars, like generics, are typically more affordable versions of brand-name drugs. Competition is here for a multiple sclerosis drug made by Biogen Inc. On Thursday, the U.S. Food and Drug ...

Mamelodi Sundowns has partnered with wellness brand, Biogen South Africa and will become the club’s official supplements partner... In the pursuit of peak performance, the collaboration ...